Tuesday, 12 Nov 2019

You are here

Most Psoriatics Go on Biologics

A cohort study of 97 patients with psoriatic arthritis (PsA) examined the prescribing practices in PsA, and found biologics are commonly initiated as the primary mode of therapy in outpatients with PsA. However, treatment modifications can be made regarding patients who are managed with apremilast alone.

Data was collected by a retrospective chart review examining the use of biologics versus oral small molecules (OSMs - methotrexate, sulfasalazine, leflunomide), and apremilast.

Among 97 PsA patients, two-thirds were on biologics, with peak use in those who were 38 to 57 years age. Biologic treated patients had better (superior) disease control (84.4% vs 66.6%; P = 0.0016) compared to OSMs. But OSMs provided slightly better control (69.5% vs 61.5%; P = 0.016) over apremilast monotherapy (13.4% of patients were on apremilast  monotherapy).

This quality improvement project reveals that in most instances, biologics are being appropriately initiated as the primary mode of therapy for patients with PsA; however, treatment modifications can be made regarding patients who are managed with apremilast alone.

Although MTX is commonly presdribed in PsA, biologics are being used consistently in practice, with the exception of use in the elderly.


The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

PSA is often misdiagnosed, and I posit that a some patients with just OA, whom happen to have psoriasis, are inappropriately on biologics

More Like This

Year in Review - Psoriatic Arthritis 2019

Major new insights into the treatment of psoriatic arthritis dominated the headlines during the past year, with a head-to-head trial comparing IL-17A inhibition with tumor necrosis factor blockade, another study considering whether methotrexate can improve outcomes with anti-TNF therapy in PsA, and an investigation into the effects of biologic therapy on bone.

EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis

Novartis has announced the results of the EXCEED trial that pitted its IL-17 inhibitor, Cosentyx (secukinumab - SEC) against Humira (adalimumab - ADA) in patients with active psoriatic arthritis. The trial demonstrated that SEC was not non-inferior to ADA, but failed to meet its primary endpoint of superiority over ADA as far as drug efficacy.

Rinvoq (upadacitinib) Effective in Psoriatic Arthritis

Yesterday, AbbVie reported the top-line study results showing the efficacy of Rinvoq (upadacitinib - UPAD) adult patients with active psoriatic arthritis who previously had an inadequate response to a biologic DMARD.

Comorbidity Worsens Axial Spondyloarthritis

Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.

One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery

Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.

The Danish National Patient Registry was used in this cohort study of incident PsA patients and their future risk of joint surgery compared to a general population cohort (GPC) between 1995-2012).